Fraud Scandal Costs GSK $3 Billion

GlaxoSmithKline agreed to plead guilty and pay $3 billion to resolve criminal and civil allegations that it illegally promoted prescription drugs and failed to report safety data, the U.S. said.
Is Tesla’s Downgrade an Opportunity for Investors
28:07 - IDDS Group co-founder and CEO Max Zanan and Jefferies Analyst Dan Dolev discuss the Tesla being downgraded with Emily Chang on “Bloomberg West.” (Source: Bloomberg)
  • Ukraine’s Jaresko: I'm Optimistic About Russia Bond Talks
  • Dell to Offer Data Storage Giant EMC $33 Per Share
  • Uber Closing In On 2014 Hack Suspect